Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy

Status:	Terminated
Conditions:	Neurology, Orthopedic
Therapuetic Areas:	Neurology, Orthopedics / Podiatry
Healthy:	No
Age Range:	6 - 20
Updated:	3/14/2019
Start Date:	May 2013
End Date:	March 30, 2016

A Phase 1b Open Label, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT-100 in Patients With Duchenne Muscular Dystrophy

The main purpose of this study is to test the safety and tolerability of different,
increasing doses of an experimental medication called HT-100 in boys and young men with
Duchenne muscular dystrophy (DMD). The study medication, HT-100, is a medicine that may help
promote healthy muscle regeneration, diminish inflammation and the resulting damage to
muscle, and decrease the scar tissue that forms in the muscles of children with DMD. In this
study, pharmacokinetic sampling, or measurements of the amount of HT-100 in the bloodstream
will also be taken.

Main Inclusion Criteria:

- Ambulatory or non-ambulatory

- Diagnosis of DMD with confirmation of minimal to no dystrophin

- Corticosteroid naive or on therapy for at least 12 months (stable dose and regimen)

Main Exclusion Criteria:

- Recent, substantial change in use of cardiac medications or medications affecting
muscle function

- Inability to undergo magnetic resonance imaging (MRI)

- Significantly compromised cardio-respiratory function

- Prior treatment with another investigational product in past 6 months

We found this trial at

sites

Cincinnati Children's Hospital Medical Center

3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229

1-513-636-4200